SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2012
PRESTIGE BRANDS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
This Current Report on Form 8-K/A is being filed as an amendment to the Current Report on Form 8-K filed by Prestige Brands Holdings, Inc. (the “Company”) with the Securities and Exchange Commission (the “Commission”) on April 2, 2012 (the “Original Form 8-K”) announcing the completion of its previously announced acquisition of the Debrox® and Gly-Oxide® over-the-counter (OTC) pharmaceutical brands sold in North America, including certain related contracts, trademarks and inventory (the “Two Brands”), from GlaxoSmithKline plc and certain of its affiliates (collectively, “GSK”). On February 2, 2012, the Company filed a Current Report on Form 8-K (the “15 Brands Form 8-K”) with the Commission announcing, among other things, the completion of its previously announced acquisition of 15 OTC pharmaceutical brands sold in North America, including certain related contracts, trademarks and inventory (the “15 Brands” and together with the Two Brands, the “GSK Brands”), from GSK on January 31, 2012. This Current Report on Form 8-K/A amends Item 9.01 of the Original Form 8-K to present certain audited financial statements of the GSK Brands and to present certain unaudited pro forma financial information in connection with the Company’s business combination with the GSK Brands. All of the other Items in the Original Form 8-K remain the same and are hereby incorporated herein by reference into this Current Report on Form 8-K/A.
Item 9.01 Financial Statements and Exhibits.
The audited financial statements listed below for the GSK Brands were included in the Company’s Current Report on Form 8-K/A which was an amendment to the 15 Brands Form 8-K and was filed with the Commission on April 16, 2012 (the “15 Brands Form 8-K/A”) and are incorporated herein by reference.
Report of Independent Registered Public Accounting Firm, PricewaterhouseCoopers LLP
Audited Combined Statements of Revenue and Direct Operating Expenses for the years ended December 31, 2011, 2010 and 2009
Audited Combined Statements of Net Assets to be Sold as of December 31, 2011, 2010 and 2009
Notes to Combined Financial Statements for the years ended December 31, 2011, 2010 and 2009
The unaudited pro forma combined financial statements listed below of the Company giving effect to the acquisition of the GSK Brands were included in the 15 Brands Form 8-K/A and are incorporated herein by reference.
Unaudited Pro Forma Combined Balance Sheet as of December 31, 2011
Unaudited Pro Forma Combined Statement of Operations for the twelve months ended March 31, 2011
Unaudited Pro Forma Combined Statement of Operations for the nine months ended December 31, 2011
Notes to Pro Forma Combined Financial Statements
See Exhibit Index immediately following the signature page to this Current Report on Form 8-K/A.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.